If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
CARDIOLOGY
ISSN 2054-3174 October 2013 • emjreviews.com
INSIDE
Review of the 61st
Annual ESC Congress 2013
Amsterdam, the Netherlands
COMORBIDITIES
HISTORY OF
NONCOMPLIANCE
ELDERLY
USE OF CONCOMITANT
MEDICATIONS
LOW BODY
WEIGHT
RENAL
DYSFUNCTION
EVERY PATIENT IS DIFFERENT.
BUT DO ORAL ANTICOAGULANTS ADDRESS THIS?
ORAL ANTICOAGULATION SHOULD
CONSIDER INDIVIDUAL PATIENT
DIFFERENCES AND NEEDS
Patient-related factors are important considerations for
determining an individual's response to oral anticoagulation
therapy.1-2 Despite advances in oral anticoagulation,
questions still remain about how patient-related
factors complicate the decision of which agent to use
and at what dose.3,4 These factors inc
CARDIOLOGY ISSN 2054-3174
COMORBIDITIES HISTORY OF NONCOMPLIANCE EL
EVERY PATIENT IS DIFFERENT. BUT DO ORAL ANTICOAGU
CONTENTS EDITORIAL BOARD.......................
CARDIOLOGY CONSISTENCY VERSUS EQUITY - CARDIOVA
EDITORIALBOARD CARDIOLOGY Dr Fernando Alfonso
Reduce Stroke Risk Protect Your Patients One tab
Ischaemic stroke: the most common thromboembolic
European Medical Journal Cardiology - October 2
Now NICE Treat PE and DVT f rtrr t ti
Foreword Dr Carl J. Lavie Professor of Medic
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
Welcome to the European Medical Journal review of
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
Ongoing issues were approached with both open- mi
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
Music can help rehabilitation process of CAD A N
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
ventricle. The retrieval is done through
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
Tour de France riders have better mortality rates
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
an epidemic of AF-related strokes if nothing is d
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
Professor Näbauer added: “A CHADS score
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
PaceWave a positive step for sleep-disordered br
ESC ANNUAL CONGRESS 2013 AMSTERDAM RAI EXHIBITION
It recommends that patients should partake i
NEW INSIGHTS INTO THE DEFINITIVE MANAGEMENT OF
Studies suggest that extending treatment wit
Prof Lip presented data from his research group c
antidotes. However, a phase II study of the Porto
Prof Büller concluded that low molecular weight
venous thromboembolism. N Engl J Med. therapy
ACE-INHIBITORS AND CARDIOPROTECTION OPEN ISSU
The evidence base for this is comprehe
cardiac uptake, and a greater rate of conversion
endothelium (+100%).10 This demonstrates
of lactate and creatinine phosphokinase from the
activation of the β-2 receptor has ben
treated with an ACE inhibitor plus a calci
In Watanabe heritable hyperlipidaemic
groups; prodrugs (captopril, lisinopril, Zofenopr
shown that one of the enhanced benefits
Comparison Hazard ratio (95% CI) Zofenopril vs
inhibitors is that Zofenopril appears to produce
A Concentrations of Lisinopril Drug concentrati
Question: Nebivolol has advantages in terms of or
REFERENCES 1. Mancia G et al. 2013 E
32. GISSI-3: effects of lisinopril and trans
THE CHANGING LANDSCAPE IN ORAL
or a patient requires urgent surgery or intervent
the adequacy of anticoagulation is usually better
confusion rather than help. The documen
relates to clinical factors.15 The dosing r
Table 1: Bleeding complications and possible meas
Table 2. Cessation of NOACs before planned surger
ENGAGE AF-TIMI (Thrombolysis in Myocardial Infa
the duration of the trial. Patients were at moder
Table 3. Phase III AF trials - dose comparisons.
One of the common challenges across these three t
those who had been randomised to warfarin.
mg actively, at randomisation or during the trial
The efficacy outcomes during the on-treatmen
disease (45% in the NOAC treatment group and 47%
Panel Discussion Question: What are the numbers
Question: How did you define non-valvular AF in th
Question: Were any patients treated with thrombol
Question: How are you going to handle the analysi
Abstract P529. Eur Heart J. 2013;34:S95. 17. Para
PRACTICAL GUIDANCE FOR STROKE PREVENTION IN ATRIA
TTR is <50%, these outcomes are in fact worse tha
warfarin. It was highlighted that, from the resul
Optimising Periprocedural Protection
REFERENCES 1. Gallagher AM et al. Risks of strok
MANAGING THROMBOEMBOLIC RISKS OF ATRIAL FIB
range – this was demonstrated in multiple clinica
models simulating drug use in patients with event
most other agents, independent of
REFERENCES 1. Go AS, Mozaffarian D, Roger
ATRIAL FIBRILLATION IN CHILDHOOD WITH FAMILIAL
well as mild pulmonary valve stenosis. At 2 years
anticoagulation in hyperthyroid patients with AF,
CONSISTENCY VERSUS EQUITY - CARDIOVASCULAR DISEAS
for more established migrant groups, such a
among South Asian patients. Whilst it is o
be counter-productive in promoting a sense
Diabetes Care. 2006;29(6):1383-5. 22. Chaturvedi
From a host of fourteen therapeutical areas, EURO
PRESCRIBING PHYSICAL ACTIVITY FOR THE P
managed in order to minimise their risk of
prescription of resistance programmes wit
2012;19(5):1005-33. 24. Reybrouck T, Mertens
INITIAL EVIDENCE IN THROMBOANGIITIS OBLITERANS (
pathologies by exerting various deleterious effec
versus aspirin27 has shown that the healing of ul
Fig. 1 ET - 1 •Vasoconstrictive Mediator effect
REFERENCES 1. Olin JW. Thomboangiitis obliter
CALL FOR PAPERS IF YOU ARE INTERESTED IN SUBMITT
NATIONWIDE FAMILY STUDIES OF CARDIOVASCULAR DISEA
At the moment, clinicians usually have to rely on
Table 1. Swedish nationwide familial relativ
NATIONWIDE FAMILY STUDIES Coronary Heart Disease
Stroke Epidemiologic evidence supports a
Atrial Fibrillation A large number of genetics st
Rate per 100,000 person years 120 100 80 6
Table 4. Familial relative risks (FRRs) for sever
disease and they represent the overall interactio
REFERENCES 1. World Health Organi
46. Forsberg L, Rydh H, Jacobsson A, et al. Kvali
thrombosis: a nationwide epidemiological study
THE BENEFITS OF RIVAROXABAN (XARELTO®) ACROSS
always includes the clinical scenarios
levels of ≥2 g/dl and transfusions were mo
Acute Coronary Syndrome Major determinants of
patient, including regular assessment of ren
16. Wallentin L et al. Ticagrelor versus clopidog
ADVERTORIAL Safe, fast, copeptin-based rule-out o
ADVERTORIAL Suggested new process based on BIC-
WHAT’S NEW Intercourse from the bedroom to the do
CARDIOLOGY 3D holography: The future of cardiolog
WHAT’S NEW Lab-grown human heart tissue beats on
CARDIOLOGY Ranexa® reduces angina in patients wit
WHAT’S NEW New drugs that target cell nucleus may
CARDIOLOGY Children still risk mutations regardl
WHAT’S NEW Cardiovascular screening every 5-10 ye
SUBSCRIBE TO THE EMJ NEWSLETTER www.news.emjrevie
Bayer HealthCare is among the world’s foremost in
ABBOTT ACCUMETRICS INC. ACTELION PHARMACEUTICALS
BUYER’S GUIDE LAERDAL MEDICAL LE CARDIOLOGUE LIT
ALBANIAN SOCIETY OF CARDIOLOGY ALGERIAN SOCIETY O
SOCIETIES NORWEGIAN SOCIETY OF CARDIOLOGY PCR PO
From a host of fourteen therapeutical areas, EURO
UPCOMING EVENTS 4th Congress of the Croatian Ass
CARDIOLOGY 17th International Congress on Advanc
SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS NEW